凯伦生物科技获得HKEX批准, 从库存代码中删除"B"标记. Kelun-Biotech gains HKEX approval to remove 'B' marker from stock code.

香港上市生物制药公司Kelun-Biotech已获得HKEX的批准,将其股票代码中的"B"标记从2026年4月14日起取消. Hong Kong-listed biopharmaceutical company Kelun-Biotech has received HKEX approval to remove the "B" marker from its stock code effective April 14, 2026. 这一里程碑意味着该公司已经达到更高的上市标准,反映了其研发管道中的进展,包括四个批准产品和多项国际合作伙伴关系. This milestone signifies the company has met higher listing standards, reflecting progress in its R&D pipeline, including four approved products and multiple international partnerships.